Verastem (VSTM) Expected to Release Earnings on Thursday

Verastem (NASDAQ:VSTM) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Verastem to post earnings of ($0.46) per share and revenue of $22.8790 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verastem Stock Down 3.5%

NASDAQ VSTM opened at $6.01 on Thursday. Verastem has a one year low of $3.43 and a one year high of $11.24. The company has a market cap of $528.10 million, a P/E ratio of -2.23 and a beta of 0.29. The business has a fifty day moving average price of $4.62 and a 200 day moving average price of $5.42. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.04.

Insiders Place Their Bets

In other Verastem news, CEO Dan Paterson sold 20,871 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $4.18, for a total transaction of $87,240.78. Following the completion of the sale, the chief executive officer owned 591,242 shares of the company’s stock, valued at $2,471,391.56. This trade represents a 3.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.94% of the company’s stock.

Hedge Funds Weigh In On Verastem

Large investors have recently modified their holdings of the business. Polar Capital Holdings Plc grew its holdings in shares of Verastem by 270.7% during the 4th quarter. Polar Capital Holdings Plc now owns 3,925,126 shares of the biopharmaceutical company’s stock worth $30,302,000 after purchasing an additional 2,866,350 shares during the period. Farallon Capital Management LLC purchased a new stake in Verastem in the 4th quarter valued at about $15,440,000. SymBiosis Capital Partners LLC acquired a new position in Verastem in the fourth quarter valued at about $15,440,000. Goldman Sachs Group Inc. lifted its position in Verastem by 504.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,495,424 shares of the biopharmaceutical company’s stock valued at $11,545,000 after buying an additional 1,248,011 shares during the last quarter. Finally, RTW Investments LP increased its position in shares of Verastem by 21.2% during the fourth quarter. RTW Investments LP now owns 6,576,306 shares of the biopharmaceutical company’s stock valued at $50,769,000 after acquiring an additional 1,150,000 shares during the last quarter. Institutional investors and hedge funds own 88.37% of the company’s stock.

Analyst Upgrades and Downgrades

VSTM has been the topic of a number of recent research reports. Alliance Global Partners restated a “buy” rating on shares of Verastem in a research report on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $18.00 target price on shares of Verastem in a research note on Thursday, July 2nd. Mizuho lowered their target price on Verastem from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Royal Bank Of Canada set a $14.00 price target on Verastem and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Verastem in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.40.

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.